MARKET

LSTA

LSTA

Lisata Therapeutics Inc
NASDAQ
4.410
+0.040
+0.92%
After Hours: 4.440 +0.03 +0.68% 17:39 09/28 EDT
OPEN
4.260
PREV CLOSE
4.370
HIGH
4.470
LOW
4.229
VOLUME
14.02K
TURNOVER
0
52 WEEK HIGH
18.60
52 WEEK LOW
4.229
MARKET CAP
34.49M
P/E (TTM)
-0.7188
1D
5D
1M
3M
1Y
5Y
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
Benzinga · 09/19 05:53
12 Health Care Stocks Moving In Friday's Intraday Session
 
Benzinga · 09/16 18:06
Why NCR Is Trading Lower By Around 23%, Here Are 42 Stocks Moving In Friday's Mid-Day Session
Gainers Kensington Capital Acquisition Corp. IV (NYSE: AMPX) jumped 35.4% to $13.54 after gaining 11% on Thursday.
Benzinga · 09/16 16:38
Life Sciences Virtual Investor Conference: Presentations Now Available for On-Demand Viewing
NEW YORK, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the September Life Sciences Virtual Investor Conference are now available for on-dema...
GlobeNewswire · 09/16 12:35
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
Company to commence trading on The Nasdaq Capital Market under Ticker Symbol “LSTA” Lisata has approximately $76 million in cash and investments following transaction close Lisata strengthens Board of Directors and Executive Leadership Team, appointing sea...
GlobeNewswire · 09/15 13:15
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Benzinga · 09/14 17:33
Why SciSparc Is Trading Higher By 68%, Here Are 48 Stocks Moving In Wednesday's Mid-Day Session
Gainers Akerna Corp. (NASDAQ: KERN) shares rose 81.2% to $0.2355 after gaining 8% on Tuesday.
Benzinga · 09/14 16:28
Caladrius rallies on approval of merger, name change to Lisata Therapeutics
Caladrius Biosciences (NASDAQ:CLBS) <a href="https://seeking...
Seekingalpha · 09/14 12:24
More
About LSTA
Lisata Therapeutics, Inc., formerly Caladrius Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The Company focuses primarily on advancing its CendR Platform technology product candidates in a range of oncology indications. Its lead investigational product candidate, LSTA1, is designed to modify the tumor microenvironment by activating an uptake pathway that allows anti-cancer drugs to penetrate solid tumors. LSTA1 actuates an active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. In addition, the Company also has clinical development programs based on its autologous CD34+ cell therapy technology platform.

Webull offers kinds of Lisata Therapeutics Inc stock information, including NASDAQ:LSTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LSTA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LSTA stock methods without spending real money on the virtual paper trading platform.